1. INTRODUCTION
===============

Depression is a commonly-occurring, life-threatening, and debilitating psychiatric disorder, with the main symptom being feeling low incessantly. The patients suffering from depression will feel sad, anxious, hopeless or restless, and may lose interest in activities which were pleasurable before; develop anorexia or overeat and have problems to concentrate or remember details. Following such negative mood and behaviours, some people with severe depression often choose suicide or other extreme behaviours \[[@R1]-[@R5]\]. Depression has been reported to be associated with severe medical disorders, such as cardiovascular disorders, Alzheimer's Disease and cancer \[[@R2]\].

Although antidepressant drug development has made huge progress, due to the various pathogenic factors involved in depression, many of the drugs fail to get remarkable effects and many patients are resistant to the treatment. Therefore, it is necessary to find new antidepressants. It has been reported that there are sex differences in depression. Women are more vulnerable to depressive disorders, compared with men, showing approximately a 2:1 ratio \[[@R7],[@R8]\]. The gender differences in depression may relate to the differences in facing pressure, but most convincingly, the frequent occurrence of depression in women is affected by hormonal changes, e.g. estrogens and progestogens \[[@R6]\]. "Estrogens" are a group of sex steroid hormones, mainly produced by the ovaries and the placenta; adrenal cortex also produces a handful of estrogens. They are produced naturally in women's bodies in three shapes, estrone (e1), 17b-estradiol (e2), estriol (e3) \[[@R9]\], of which estradiol has more bioactivity under normal conditions \[[@R10]\]. Estrogens are known as important hormonal signals, but their effects are not limited. Clinical and rodent studies have shown that estrogens have profound and diverse effects on the brain, including modulation of neuronal proliferation, survival and plasticity and have effects on CNS through the neurotrophic and neuroprotective actions on central parts of the brain such as hippocampus, cortex, amygdala, and basal forebrain \[[@R11]-[@R13]\]. The effects are related to mood and cognition, so that the change of estrogen levels may be implicated with depressive behaviours and the treatment of estrogen may be a target for depression.

Ghrelin, which was identified for the first time in the rat stomach in 1999, is a novel peptide of 28 amino acids. It can be mainly synthesized in stomach and other places like small intestine, pancreas, lung, kidney, and ovaries. Some reports proved that ghrelin can be expressed in the hypothalamus or some other places in the brain \[[@R14]-[@R19]\]. Ghrelin is the endogenous ligand of the growth hormone secretagogue receptor 1a (GHS-R1a), which is expressed in agouti-related peptide/neuropeptide Y (AgRP/NPY) neurons in the arcuate nucleus of the hypothalamus \[[@R1]\]. The main known function of ghrelin is to increase pituitary release of growth hormone (GH), from anterior pituitary cells \[[@R17]\]. And several studies have indicated that the effect of ghrelin is *via*both direct and indirect pathways, including the vagal afferent nerve. In addition, the administration of ghrelin stimulates food intake, carbohydrate utilisation and an increase in the body weight, suggesting a role for ghrelin in energy balance. Nowadays, many references have been reported that ghrelin also has regulatory functions such as learning, memory, reward, motivation and neuroprotection, which have different levels of destruction when suffering from depression \[[@R18],[@R19]\]. So, it is not difficult to speculate that ghrelin may play a key role in depression.

What is the curative effect of estrogen or ghrelin treatment in depression, and what are the mechanisms of their antidepressant-like actions? In this review, we will provide a summary of recent reports and try to find the link between ghrelin and estrogen for depression.

2. GHRELIN
==========

2.1. The Link between Central Ghrelin, Food Intake and Depression?
------------------------------------------------------------------

Ghrelin is bound with ghrelin receptor named by GH secretagogue receptor (GHS-R), and produces physiological function. GHS-R has two isoformes, Ia and Ib \[[@R16]\]. GHS-R Ia has more pharmacological function compared with Ib. GHS-R1a is highly concentrated in hypothalamus, for the regulation of eating behaviors. However, hypothalamus is not the only place to express ghrelin receptors \[[@R20],[@R21]\], many studies have showed that GHSR1a is significantly expressed within the other regions of CNS \[[@R22]\], such as hippocampus, amygdala and dorsal raphe nucleus (DRN) \[[@R23]\]. The abundant expression shows that ghrelin receptors are involved in the numerous biological functions, which are extra-hypothalamic \[[@R18],[@R19]\]. The distribution of ghrelin and its receptors agrees with the surveys for depression and eating disorders.

Ghrelin is linked with the behaviours of food intake. It has been reported that microinjection of ghrelin in the hippocampus and DRN increased rat feeding behaviors in a dose-dependent manner \[[@R24]\] and intracerebral administration of ghrelin also increased food intake both in mice and rats \[[@R25],[@R26]\]. Nakazato *et al*., 2001 \[[@R26]\] reported that ICV administration of ghrelin increased food intake in GH deficient mice, suggesting that ghrelin increased food intake in GH independent manner. These results indicated that ghrelin plays an important role in central regulation of the feeding.

In clinical studies, two eating disorders are characterised by abnormal patterns of weight regulation and eating behaviors \[[@R27]\], named anorexia nervosa (AN) and bulimia nervosa (BN) \[[@R27]\]. AN leads to more deaths than any other psychiatric disorders, which is characterised by loss of body weight, obsessive thoughts of food, self-starvation, and disturbed body image \[[@R28]\]. AN patients have shown a high level of ghrelin \[[@R29]\], which is paradoxical to the characters of AN, some researchers suggested that ghrelin's high levels in AN patients may be an organism trying to stimulate appetite during calorie restriction \[[@R30]\]. On the contrary, patients with BN eat too much food. Patients with BN have been reported to have decreased levels of ghrelin \[[@R31],[@R32]\]. These evidences have proven that ghrelin plays a key role in the pathopoiesia and treatment of eating disorders.

There is a correlation between food intake behaviors and depression. Different types of stresses have different response to food intake; melancholic is associated with hypercortisolism, anorexia and weight loss, while atypical depression is associated with high anxiety, carbohydrate craving and weight gain \[[@R18],[@R33]\]. Therefore, it is reasonable to assume that ghrelin may play a role in depression.

2.2. Antidepressant-like effect of Ghrelin
------------------------------------------

To prove the antidepressant-like effects of ghrelin, strong evidences have been found in both rodents and humans. Ghrelin plasma levels were obviously increased 4 fold after restricting food intake of mice \[[@R23]\], the increase in ghrelin levels were also observed after fasting \[[@R36]\]. We can use calorie-restricted mice as the models to simulate the increase of ghrelin. It has been reported that calorie-restricted mice spent less immobile time in forced swimming test (FST), and showed more time in the open arm of the elevated plus maze test (EPM) \[[@R18]\]. However, these antidepressant-like effects did not occur in the genetic blockade of ghrelin signalling in GHSR 1a knockout (Ghsr1a-/-) mice with the same calorie restriction. The antidepressant-like effects were also produced by subcutaneous ghrelin injection. C57BL6/J mice with subcutaneous ghrelin injection showed significantly less depression-like behaviors in the EPM and FST \[[@R37]\], and GHSR knockout mice had more depressive-like behaviors. In addition, acute ghrelin reverses depression-like behaviors induced by bilateral olfactory bulbectomy in mice \[[@R38]\] and serotonin transporter (SRET), delta opioid receptor, and interleukin 1 beta *et al*., could be involved in the antidepressant-like effects of ghrelin.

In clinical studies, patients with major depression (MDD) have lower plasma ghrelin levels, and the antidepressant effects have been reported following ghrelin administration \[[@R31]\]. The evidence both in rodents and humans showed that when ghrelin levels upgrade, symptoms of depression can be alleviated, and because ghrelin levels can be increased both in endogenous and injection, it is more meaningful to study ghrelin's antidepressant-like effects.

2.3. The mechanisms of Ghrelin's Antidepressant-like Action
-----------------------------------------------------------

Ghrelin, as a new endogenous antidepressant, must have its benefits, the mechanisms of ghrelin's antidepressant-like action have become the most interested topics for researchers. Basic and clinical studies have provided evidence that the serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) neurotransmitter systems \[[@R39]\] are involved in the pathology and/or behavioral manifestations associated with depression, which are called the monoamine hypothesis. Moreover, depression has been associated with alterations of growth factors, particularly brain-derived neurotrophic factor (BDNF), and the related signalling factors associated with the BDNF signalling molecules, for instance cAMP, CREB \[[@R40]\]. Recently, studies demonstrated that ghrelin may play a major role in hippocampal neurogenesis in the treatment of depression \[[@R41]\]. In this review, we will discuss the mechanisms of ghrelin's antidepressant-like action through the hypotheses which are related to depression.

2.3.1. Ghrelin and Monoamine Hypothesis
---------------------------------------

The abnormal function of central serotonergic system is an important hypothesis for the mechanisms of depression \[[@R36]\]. There are strong evidences to prove that the dysfunction of 5-HT ergic system is related to depression and other mood disorders.

DRN neurons, especially neurons which utilize 5-HT as their major neurotransmitter, might be involved in the neuropathogenesis of ghrelin. Acute central administration of ghrelin, increased 5-HT and 5-HT receptors mRNA in mice DRN \[[@R45],[@R47]\]. Studies in Ghsr1a knock-out mice showed a decreased mRNA expression of 5-HT receptors in DRN relative to their wild-type littermates \[[@R45]\]. The 5-HIAA levels and 5-HT receptors mRNA also increased with acute central ghrelin administration in amygdala \[[@R45]\]. From the above information, we conclude that the central serotonin system is a target for ghrelin.

Ghrelin receptors positively interact with not only 5-HT receptors but also dopamine (DA) receptors \[[@R42]\]. The action of ghrelin in the ventral tegmental area (VTA) is involved in dopaminergic neuronal firing and DA turnover, which is dependent on GHSR1a receptors, *via*glutamatergic inputs \[[@R29],[@R48]\]. Besides, the signal activated by ghrelin can reach the ARH where mainly the release of naradrenaline (NA) increases \[[@R51]\]. Because of the importance of monoamine hypothesis, the link between ghrelin and other receptors will be well studied in the future.

2.3.2. BDNF and Related Signal Transduction Pathways in Ghrelin's Antidepressant-like Effects
---------------------------------------------------------------------------------------------

Most of the works on neurotrophic factors' hypothesis were focused on BDNF \[[@R40],[@R49]-[@R51]\]. Several strong evidence have proven that BDNF, a 27-kDa protein, acts as a key factor in the development of brain, such as neural plasticity, memory and learning \[[@R50],[@R52]-[@R54]\]. Stress leads to the decrease of BDNF levels, resulting in the abnormal activity of neurons and the administration of BDNF produces an antidepressant-like effect \[[@R49]-[@R52]\].

Ghrelin has been proved to improve cognitive ability in diabetic rats by improving the expression of BDNF and CREB. BDNF (F) knock-out mice had abnormal eating behaviors, and antidepressants treatment alleviated abnormal behaviors and increased BDNF levels. From the finding, we make an assumption that ghrelin has effects on the levels of BDNF. Evidences have proved that ghrelin stimulated the expression of CREB and pCREB \[[@R53]\]. However, whether other receptors like TrkB that activate BDNF expression are influenced by ghrelin is still unknown, and the works on other neurotrophic factors are still lacking.

2.3.3. Ghrelin's Treatment Increases Hippocampal Neuro-genesis
--------------------------------------------------------------

Neurogenesis, a process of generating functionally integrated neurons from progenitor cells \[[@R54]-[@R63]\], has been proved to persist in adulthood in several mammals, including birds, rodents, monkeys, and humans. The subventricular zone (SVZ) and the subgranular zone (SGZ) are two major neurogenic zones where progenitor cells are found and continue to produce new neurons \[[@R55]\]. There has been much attention focused on neurogenesis in the hippocampus, because this structure is important in the process of learning, memory, and emotional responses.

The neurogenesis can be regulated by many factors, including environmental changes and pharmacological treatments \[[@R55]\]. Many kinds of stress can decrease neurogenesis of adults, including predator odor \[[@R64]\], social stress \[[@R65]\] and acute and chronic restraint stress \[[@R66]\]. The decrease of hippocampal neurogenesis by stress might be an important mechanism related to depressive disorders. Since many conventional antidepressant treatments increase neurogenesis in the adult hippocampus \[[@R68]\], we can conclude that neurogenesis may be linked to their antidepressant-like behavioral effects.

Several studies have reported that ghrelin enhances neurogenesis. Firstly, ghrelin was known to increase neurogenesis in the fetal spinal cord of rats and the nucleus of solitary tract and the dorsal motor nucleus of vagus in adult rats \[[@R69]\]. Recently, ghrelin was proved to directly increase hippocampal neurogenesis \[[@R71],[@R72]\]. Systemic administration of ghrelin to the ghrelin receptor knockout mice (Ghsr1a-/-) showed lower number of progenitor cells in the DG compared with those of the wild-type controls \[[@R69],[@R71]\]. In both *in vitro* and *in vivo* studies, ghrelin treatment stimulates neurogenesis, and the synthetic GHS-R agonist hexarelin has the same effect \[[@R51]\]. One of the ways for testing neurogenesis is *via*bromodeoxyuridine(BrdU). The number of BrdU- labeled cells shows the concentration in cell proliferation, reports have demonstrated that stress can reduce the BrdU-labeled cells in hippocampus \[[@R69]\], and the ghrelin treatment can enhance the BrdU- labeled cells in many part of the brain, including hippocampus. Although the role of ghrelin in stimulating neurogenesis is still unknown, it has been proved that ghrelin may act as an effective factor for neurons by controlling apoptotic pathways \[[@R72]\].

3. ESTROGEN
===========

3.1. The Sex Differences in Depression and Reproductive Depression
------------------------------------------------------------------

The sex differences may lead to a different response to stress. From the introduction, women are 2 times more sensitive to stress 2 times than men. Rodent behaviour experiments revealed that female rats showed more mobility in open field test (OFT), greater open arm time in the EPM and lesser immobile time in the FST \[[@R73]\].

But sex differences in depression do not manifest throughout life. Before adolescence, the chance to suffer from depression for girls and boys are 1:1 \[[@R74]\]. From the onset of puberty, women have 2 to 3 times greater risk of depression than men \[[@R76]\]. But the sex ratios become equal again after menopause \[[@R75]\]. Women have high risk of depressive disorders during menstruation, pregnancy, post-partum and menopausal periods \[[@R73]\]. Recent US guidelines advised that all midlife women should be screened for depression, as midlife women (45-55 years old) \[[@R82]\] are more likely to suffer from depression than at other ages \[[@R78]-[@R80]\].

This result suggests that the change of sex hormones during the perimenopause and menopausal may play a key role in the manifestation of depression. And other researchers have found that women during perimenopause are more likely to suffer from depression than during postmenopause \[[@R85],[@R86]\].

3.2. The Link between Estrogen and Depression
---------------------------------------------

Since sex hormones are related to the depression in women, estrogens - one kind of major sex hormones secreted by ovaries, may play an important role in the treatment of depression.

### 3.2.1. Estrogen and Depression

Reproductive aging in women is associated with the decrease of sex hormones (estradiol and estrone) \[[@R89]\]. Researchers have found that women during menopause were more likely to suffer from depression, when estrogen levels were decreased \[[@R76]\]. And women with depression showed lower levels of estradiol than control subjects \[[@R90]\]. Based on the reports, we conclude that the low levels of estrogens may be associated with depressed mood.

Ovariectomy (OVX), is a menopausal animal model, based on resection of ovaries, resulting in a depressive state. OVX animals are used to mimic the circulation levels of estrogen of women during menopause. Growing literatures suggested that OVX induced estrogen insufficiency \[[@R91]\]. Long-term ovariectomised mice displayed a significant lesser open arm activity in the EPM \[[@R82]\] and lesser struggling time in the FST \[[@R91],[@R92]\] than control animals. When given 4-months chronic stress to the OVX mice, results showed a significantly less struggling time in the FST compared to 2-weeks stress mice \[[@R91]\], which showed that long-term OVX may have greater danger to suffer from depression.

Estrogens have multiple functions in the brain \[[@R93]\]. There are two major subtypes of estrogen receptors, ER alpha and ER beta \[[@R94]\]. ERα is particularly expressed in the hypothalamus, preoptic area and amygdala, which are responsible for affective, motivational and cognitive responses \[[@R77],[@R94]\]. ERβ is particularly expressed in the hypothalamus, hippocampus, cerebral cortex, which may be related to the mechanisms of the antidepressant-like effects \[[@R95],[@R96]\]. When women were treated with the mixed estrogen receptor antagonist, tamoxifen, the patients were more likely to suffer from depression \[[@R76],[@R97]\]. The same evidence was observed in the experiments of animals \[[@R96],[@R97]\], so as to say that the abnormal ER expressions may lead to the fluctuation of estrogen levels, and cause mood disorders.

### 3.2.2. Antidepressant-like effects of Estrogen

Ovarian hormones exert anti-depressive actions in perimenopausal depression \[[@R82]\]. Also, Hormone replacement therapy (HRT) is a well-used therapy for this purpose. Estrogens, because of the functions in promoting neuronal growth, enhancing monoaminergic activity, and regulating the hypothalamic-pituitary-adrenal (HPA) axis \[[@R98]\], are considered to produce antidepressant-like effects.

Most studies on animal models are focussed on ovariectomised rats and mice \[[@R99]\], given that both acute and chronic treatment with 17-estradiol (the most well-known kind of estrogens) decreased the immobility time in the FST and tail suspension test (TST) \[[@R100]\], and increased the time spent in open arms in the EPM \[[@R101]-[@R103]\], such behaviour tests are well used in the screening of novel antidepressants, and the behaviours after estrogen proved the antidepressant-like effects of estradiol in OVX females. E2's antidepressant-like effects may relate to many factors, including the intra-cellular estrogen receptors (ERs), ERα and ERβ. For example, the ERs agonists ethynyl-estradiol (EE2) and diarylpropionitrile (DPN), induced antidepressant-like effects after an acute treatment \[[@R104]\]. After the chronic administration (7 or 14 days) of the agonist to ERs, E2 benzoate, also showed the decreasing immobility time in the FST \[[@R105]\]. And antagonists of ERs can block the antidepressant-like effects of Estrogen replacement therapy (ERT) \[[@R104]\].

In clinical studies, ERT was proved to have significant effects on improving mood disorders after menopause \[[@R77]\]. Six women were treated with estradiol, the ERT-group showed a decrease of depressive symptoms compared to control group \[[@R96],[@R106],[@R107]\]. Therefore, estrogen may be helpful for the depressive treatments, ERT may be a special and effective way to cure reproductive depression.

3.3. The Mechanisms of Estrogen's Antidepressant-like Actions
-------------------------------------------------------------

From the above description, we already simply understand the three hypotheses for antidepressant-like actions. They are monoamine hypothesis, neurotrophic factor hypothesis and neurogenesis hypothesis. In this part, we will list the reports and explore estrogens' mechanisms based on the hypotheses which are related to depression.

### 3.3.1. Estrogen and 5-HT

Wealth of data demonstrated that sex hormones are related to the regulation of serotonergic system \[[@R108]-[@R138]\]. The decrease in estrogens results in a reduction in 5-HT production \[[@R109]\], and the antidepressant treatment of estrogen has been proved to result in the up-regulation of 5-HT transporters and receptor expression \[[@R111]\] and increase the 5-HT levels. Although estrogens still have not demonstrated the effects on all 5-HT receptors, many reports have proven that manipulation of estrogen levels has effects on 5-HT1A receptors \[[@R112]\] and 5-HT2A receptors \[[@R113]\], which are related to mood disorders \[[@R114]\]. Table **[1](#T1){ref-type="table"}**. shows the previous studies related with estrogen and 5-HT \[[@R123]-[@R138]\].

According to the studies, both acute and chronic treatments of estradiol on both postmenopausal women and OVX animal models showed that estrogen can increase 5-HT2A receptor mRNA in the DRN and 5-HT2A receptor binding in the frontal cortex, anterior cingulated and other pieces \[[@R115],[@R116]\]. The 5-HT agonist meta-chlorophenylpiperazine (m-CPP) showed a better response to cortisol following estrogen, and the effects on 5-HT levels were blocked by the antagonists of 5-HT receptors. Estrogen receptors are expressed in 5-HT nucleus in DRN, and ERβ seem to be more effective to 5-HT system than ERα. In animal studies, after estrogen treatment for ovariectomised rats, the models showed increased 5-HT transporter (SERT) and 5-HT receptors mRNA in the dorsal raphe, while the estrogen receptor ERβ antagonist tamoxifen blocked these effects \[[@R109],[@R115]\], suggesting that ERβ mediated the process between estrogen and 5-HT. Not only 5-HT, estrogen also have positively modulation on NE network by increasing a1B NE receptors \[[@R119]-[@R121]\] and DA synthesis \[[@R122],[@R123]\].

### 3.3.2. Estrogen and BDNF

It has been known that stress decreases BDNF expression in several parts of brain, and the abnormal BDNF signalling is related to depression. Women have higher mean plasma BDNF levels than men \[[@R139]\], and women during adulthood have higher BDNF levels than amenorrheic or postmenopausal women \[[@R140]\], the sex difference and age-dependence of BDNF levels were explained by estrogens. There has been a wealth of data proving that low estrogen and BDNF levels were found in ovariectomised animals \[[@R14]\]. Estrogen may act as one of factors influencing the levels of BDNF mRNA and protein expression in female patients, and BDNF signalling could be related to the mechanism.

Results demonstrated that estrogen replacement no matter long-term (5 to 25 weeks) or short-term (72h to 5 days) increased BDNF mRNA levels in hippocampus, cortex and spinal cord \[[@R141],[@R142]\], and recently, 17b-E2 has been found to increase protein levels of BDNF \[[@R143]\]. Not only the levels of BDNF, estrogen were also reported to influence the levels of proteins which are in relation to BDNF. Evidences have proven that E2 increased CREB protein expression, as well as CREB phosphorylation (P-CREB) in the medial and basomedial subdivisions of amyadala, while on the other hand, E2 increased P-CREB immunolabeling but did not increase CREB protein levels in the CA1 and CA3 regions of hippocampus. And exogenous estradiol administration to OVX rats has been proved to increase BDNF through TrkB \[[@R144]-[@R146]\]. From the above information, we can conclude that the CREB signalling pathway and BDNF' s receptor TrkB are likely to activate BDNF expression following estrogen treatment.

### 3.3.3. Estrogen and Neurogenesis

As ovariectomised rodents suffered from depression, following an increasing cell death \[[@R150]\], and estrogen treatment reversed stress induced cell death. Therefore, we have hypothesis that estrogen enhances hippocampal neurogenesis to protect females from stress. The effects of estrogen in hippocampal neurogenesis have recently been reviewed in both *in vivo* and *in vitro*. *In vivo*, acute estradiol treatment within 4 hours significantly increased the proliferation of neurons and the survival of new neurons in female rats and voles \[[@R150],[@R151]\], while chronic (60 days) estrogen increased cell proliferation in middle-aged C57B1/6 mice \[[@R152],[@R153]\]. And *in vitro*, estrogen could increase the proliferation and survival of new neurons in rats \[[@R154]-[@R156]\]. The effects were abolished by ICI 182, 780, an estrogen receptor antagonist \[[@R148]\], which showed that effects of estradiol on the enhancement of hippocampal neurogenesis were mediated by estrogen receptors. And some evidence suggests that ERβ may be more involved in neurogenesis than ERα \[[@R149]\].

4. GHRELIN AND ESTROGEN
=======================

The plasma levels of ghrelin have sex differences and can be age-dependent \[[@R157]-[@R159]\]. In young women, ghrelin levels were 3 times higher than in young men \[[@R158]\] and ghrelin levels were significantly lower in middle-aged women while had no difference between young and elderly men \[[@R159]\]. In this part, we will pay attention to link ghrelin with estrogen, and try to find the common effects on depression.

4.1. Ghrelin and Estrogen have Mutual Promoting Effects
-------------------------------------------------------

As ghrelin expressions were higher in females and showed age-related changes, estrogen may play a key role in ghrelin expression. Numerous studies reported that estrogen up-regulates ghrelin level act as a positive feedback mechanism to ghrelin. 6-month or 24-month long term treatment with estrogen, increased ghrelin levels \[[@R160],[@R161]\], and oral treatment had a better effect than the transdermal treatment \[[@R159]-[@R162]\]. Some data suggested that estradiol supplementation increased total ghrelin concentration in postmenopausal women \[[@R163]\], while others suggested increased active ghrelin concentrations by 14%, without affecting total ghrelin concentrations \[[@R164]\]. These evidences suggested that estrogen may regulate ghrelin expression by increasing ghrelin secretion or enhancing hypothalamo-pituitary sensitivity to ghrelin. Further animal studies proved that estrogen may have a direct effect on ghrelin expression. Treating the rats estrogen for 8h significantly increased the level of ghrelin production and ghrelin mRNA expression \[[@R167]\], and ICI-182 780 (a pure ER antagonist) completely removed the effect of estrogen, suggesting that estrogen may influence ghrelin through ER, and ERα is more effective.

On the other hand, ghrelin also stimulates estrogen secretion. In past studies, the basal estradiol secretion during 24 h was 10.22 ± 0.39 pg/ml, while after the addition of 250 and 500 pg/ml of ghrelin, the estradiol secretion significantly increased to 12.14 pg/ml and 14.93 pg/ml \[[@R169]\]. The result suggested that ghrelin may have a modulatory effect in the ovary and may play a key role in the reproductive function.

4.2. Ghrelin Suppresses LH Pulse Frequency
------------------------------------------

E2 shows a negative feedback inhibition of luteinizing hormone (LH) \[[@R170],[@R171]\], the highest level of estradiol decreases LH level \[[@R172]\], and after postmenopausal, women's plasma LH has a remarkable increase and LH mRNA expression increases \[[@R173]-[@R175]\], the same results have been shown in the OVX animals \[[@R176]\]. Estradiol treatment can decrease LH concentration, at the low dose \[[@R176]\]. As ghrelin may play a role in regulating the hypothalamic-pituitary-ovarian axis, recent studies reported that ghrelin modulated LH secretion \[[@R177]\]. Both 36-h fasting and intracerebroventricular injection of 20 mg/kg ghrelin in mice and ovariectomised mice decreased LH levels \[[@R168],[@R178]\]. The same results were also shown in adult ovariectomised rhesus monkeys \[[@R179]-[@R181]\], when treating them with a 5-h ghrelin (100-150 ug/h), the levels of plasma ghrelin increased 2.9 fold of baseline and the group with ghrelin significantly showed a decreased LH pulse frequency, while the group with saline remained unchanged \[[@R181]\].

In clinical studies, reports showed that ghrelin reduced plasma levels of LH in patients with major depression \[[@R182]\]. CNS may be a key region for ghrelin to work on the LH regulation \[[@R183]\]. As NPY and AGRP have been shown to suppress pulsatile LH release in the OVX mammals \[[@R184],[@R185]\], and ghrelin increased the synthesis of both NPY and AGRP \[[@R186]\], it can be supposed that ghrelin may exert its effect by promoting the secretion of NPY and AGRP \[[@R187]\], the hypothesis was proved in an experiment that the action of ghrelin on LH was abolished in double knockout mice \[[@R181],[@R187]\]. Others think that ghrelin inhibits the action of LH secretion by corticotropin releasing hormone (CRH) release \[[@R188]\], because when pre-processed with astressin B (a nonspecific CRH receptor antagonist) \[[@R189]\], it abolished the decrease of LH \[[@R188]\]. Although the mechanism is still not clear, but it seems reasonable to assume that ghrelin can be a potential regulator of reproductive function.

4.3. Estrogens as Facilitators of Antidepressant Drugs
------------------------------------------------------

Estrogen not only be used as an individual antidepressant medication, but also be combined with other traditional antidepressant drugs, since the antidepressant-like effects of several kinds of drugs can be improved by the addition of estrogen \[[@R109],[@R190]-[@R193]\]. Men and women have difference in the response of antidepressants and these differences may be largely due to the presence of estrogen \[[@R109]\]. The serotonin re-uptake inhibitors (SSRIs), which increase 5-HT levels in the CNS \[[@R195]\], may have a similar mechanism with ghrelin. Animal studies have proven that SSRIs combined with estradiol produce enhanced antidepressant-like effect in females in the FST \[[@R86],[@R194]-[@R196]\]. And in clinical studies, SSRIs combined with estradiol treatment decreases the severity of depressive symptoms in perimenopausal women more effectively than SSRI therapy alone \[[@R197]\].

From the earlier discussion, we have already observed that ghrelin could be used as a new candidate of the antidepressant, and the mechanism of ghrelin's antidepressant-like action may be related to monoamime hypothesis especially 5-HT. Therefore, estrogen treatment (ET) could produce additional antidepressant-like effect with ghrelin.

5. CONCLUSIONS
==============

Ghrelin is not only linked to the feeding behaviour and energy balance, but also has antidepressant-like effects. Evidence both on animal behaviour studies using FST, EPM and human studies in MDD have shown that the increase of ghrelin levels reduced depression-like behaviours, and the antagonism of ghrelin receptor Ghsr1a blocked the effects. The mechanisms of ghrelin's antidepressant-like actions may be explained in three hypotheses, 1) ghrelin enhances the levels of monoamines and their receptors in some regions of brain, such as increases the levels of 5-HT and the receptors 5-HT1A in dorsal raphe and amygdale; 2) ghrelin improves expression of BDNF and CREB/pCREB; 3) ghrelin enhances neurogenesis.

The link between ghrelin and estrogen has been discussed in this review. As ghrelin levels were age-dependent and higher in women than men. Evidence proved that estrogen enhanced the levels of ghrelin mRNA expression and ghrelin production, and ghrelin also had positive feedback regulation in estrogen secretion. Furthermore, studies showed that ghrelin regulated HPO axis. In addition, estrogen combined with other traditional antidepressant drugs showed better effects than antidepressant drugs alone. Ghrelin and estrogen may have an additional effect for the treatment of depression. However, further study is needed to confirm whether or not combined treatment with ghrelin and estrogen produce antidepressant-like effects.

In this review, we demonstrated the antidepressant-like effects of ghrelin and estrogen. Also, we propose the viewpoint that the combination of estrogen and ghrelin produces antidepressant-like effects. This review provides more useful information to clarify mechanisms of antidepressant effects of ghrelin and ghrelin's effects on depression.
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###### 

Estrogen and 5-HT: animal studies \[118\].

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Founder                                                           Parameter                          Effect   Brain region
  ----------------------------------------------------------------- ---------------------------------- -------- ------------------------------------
  1.Di Paolo, Diagle, Picard, and Barden (1983) \[123\];\           5-HT turnover                      ↑        Dorsal raphe, amygdale
  2.Johnson and Crowley (1983) \[124\];\                                                                        
  3.Morissette, Levesque, Belanger, and Di Paolo (1990) \[125\];\                                               
  4.Munaro (1978) \[126\].                                                                                      

  1.Cone, Davis, and Goy (1981) \[127\];\                           5-HT synthesis/release SERT/mRNA   ↑        Dorsal raphe,\
  2.Pecins-Thompson, Brown, Kohama, and Bethea (1996) \[128\];\                                                 SCN, median eminence VMH, LS, VN\
  3.Cohen and Wise (1988) \[129\];\                                                                             basolateral amygdala Dorsal raphe
  4.McQueen *et al*. (1996) \[130\];\                                                                           
  5.Thomas *et al*. (1997) \[131\].                                                                             

  1.Thomas *et al*. (1997) \[131\]                                  5-HT1A binding/mRNA                ↑        Midbrain

  1\. Biegon *et al*. (1983) \[132\];\                              5-HT1A binding/mRNA                ↓        Cortex, limbic areas\
  2. Osterlund, Halldin, and Hurd (2000) \[133\];\                                                              dorsal raphe
  3. Osterlund and Hurd (1998) \[134\];\                                                                        
  4. Pecins-Thompson and Bethea (1999) \[135\].                                                                 

  1.Cyr, Bosse, and Di Paolo (1998) \[114\];\                       5-HT2A binding/mRNA                ↑        Frontal CTX\
  2. Fink and Sumner (1996) \[116\];\                                                                           anterior cingulate olfactory CTX,\
  3. Sumner and Fink (1995) \[137\];\                                                                           NA piriform CTX\
  4. Sumner *et al*. (1999) \[138\].                                                                            dorsal raphe
  --------------------------------------------------------------------------------------------------------------------------------------------------
